Travere Therapeutics Inc faces challenges as its stock experiences a notable decline.
Travere Therapeutics Inc (NASDAQ:TVTX) is facing headwinds as its stock slid by 2.11% in today's trading session, closing at CA$60.27. This decline comes despite recent positive developments regarding patent allowances for its key drug, FILSPARI.
Advertisement
Travere Therapeutics Inc
TVTX.US
TVTX.US
Travere Therapeutics Inc
WealthAwesomeMarket cap
$5.53B
52W high
$68.73
52W low
$22.59
1W change
-2.05%
Beta
1.06
Analyst Price Targets
Based on 15 analysts covering TVTX · as of Sep 25, 2026
Wall Street analysts forecast TVTX stock price to rise 22.2% over the next 12 months.
Consensus
Strong Buy4.60 / 5.00
Avg. Target
C$75.21
+22.2% Upside
Previously C$74.21 on Sep 17, 2026
Current Price
C$61.57
Last close
Analyst Breakdown (15 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TVTX's historical volatility
30-Day Vol
34.8%
Annualized
90-Day Vol
37.2%
Annualized
Trend (90d)
+33.0%
Annualized drift
90d Mean
C$69.27
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$64.04 | C$56.79 – C$72.21 |
| 60 trading days | C$66.60 | C$56.19 – C$78.93 |
| 90 trading days | C$69.27 | C$56.25 – C$85.29 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as the company's reliance on a single product, coupled with leadership changes, raises concerns about its future performance and market positioning.
2.11% decline in stock price today
Travere Therapeutics' stock is now trading at a lower valuation compared to its peers, reflecting investor concerns about its future growth prospects.
Bull case
The recent patent allowance for FILSPARI could strengthen its position in treating rare kidney diseases, which might lead to increased revenue in the future.
Bear case
The company’s heavy reliance on FILSPARI and ongoing net losses create vulnerabilities to competition and regulatory changes, potentially affecting its long-term financial stability.
Recent Developments
Advertisement
Travere Therapeutics recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent related to FILSPARI, aimed at treating focal segmental glomerulosclerosis. This development was expected to improve the company's market position, yet the stock still faced a decline as investors consider the risks of depending on a single product.
Leadership Transition
The announcement of a planned CEO transition, effective December 2026, has added to investor uncertainty. Dr. Eric Dube will step down, and Bradley L. Campbell will take over. While Campbell brings relevant experience, this leadership change raises questions about the company's strategic direction and execution in a highly competitive market.
Market Reaction
The market's reaction to Travere Therapeutics' recent news shows a cautious sentiment among investors. The stock's decline today reflects concerns over its heavy dependence on FILSPARI and the potential risks associated with leadership changes, which could impact future growth and profitability.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
